DSIJ Mindshare

Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP

Aurobindo Pharma Limited announced obtaining the last approval from the US Food & Drug Administration (USFDA) for Rivaroxaban Tablets USP, 2.5 mg.

DSIJ Intelligence-1 0 164 Article rating: 5.0

The biosimilars division alongside niche product development represents Aurobindo Pharma's main focus areas where its 1500 scientists dedicate their efforts.

Medical Equipment & Supplies Expands Global Reach in Medical Devices; Secures USFDA Registration

Company's products are available both online, through its proprietary store and major e-commerce platforms, and offline, with a presence in over 22,000 retail touchpoints across 460+ towns in India.

DSIJ Intelligence-1 0 186 Article rating: 5.0

The company's wholly-owned subsidiary, Nureca Technologies Pvt Ltd, specializes in manufacturing medical devices with an annual capacity of 8 lakh units.

Pharma Company Has Received Final Approval From United States Food and Drug Administration For Abbreviated New Drug Application

The company has a market cap of over Rs 1 lakh crore and the stock is up by 13 per cent from its 52-week low of Rs 1,310.05 per share.

DSIJ Intelligence-1 0 428 Article rating: 4.7

The company has a market cap of over Rs 1 lakh crore and the stock is up by 13 per cent from its 52-week low of Rs 1,310.05 per share.

RSS
123
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR